Sentinel node biopsy for high-risk nonmelanoma cutaneous malignancy

Area of Science:

• Oncology
• Dermatology
• Surgical Pathology

Background:

• Cutaneous nonmelanoma malignancies represent a significant oncologic challenge.
• Accurate staging of regional lymph node metastasis is crucial for treatment planning and prognosis.
• Current staging methods may not adequately detect occult (hidden) metastases in high-risk cases.

Purpose of the Study:

• To assess the feasibility of sentinel lymph node biopsy (SLNB) for staging regional lymph node metastasis.
• To evaluate the accuracy of SLNB in detecting occult metastases in patients with high-risk cutaneous nonmelanoma malignancies.
• To determine the sensitivity and negative predictive value of SLNB in this patient population.

Main Methods:

• A consecutive case series of patients with high-risk nonmelanoma cutaneous malignancies and no clinical evidence of lymph node metastasis.
• Sentinel lymph node biopsy performed using a combination of lymphoscintigraphy, blue dye, and intraoperative radiolocalization.
• Sensitivity and negative predictive value calculated by comparing SLNB results with completion lymphadenectomy and/or clinical follow-up.

Main Results:

• Twenty-four patients underwent SLNB for 29 nodal basins; primary diagnoses included squamous cell carcinoma, Merkel cell carcinoma, and adenocarcinoma.
• Seven patients (29%) had a tumor-positive sentinel node, indicating occult metastasis.
• The overall sensitivity of sentinel node staging was 88%, with a negative predictive value of 0.94.
• No recurrences were noted in sentinel node-negative basins at a median follow-up of 10 months.

Conclusions:

• Sentinel lymph node biopsy is a viable and minimally invasive procedure for staging occult regional lymph node disease.
• SLNB can effectively identify patients with nonmelanoma cutaneous malignancies who require further treatment.
• Further research is recommended to validate these findings and establish formal clinical guidelines.